<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934061</url>
  </required_header>
  <id_info>
    <org_study_id>TZSA2</org_study_id>
    <nct_id>NCT02934061</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain</brief_title>
  <official_title>A Phase III, Multicenter, Randomized Study to Assess the Efficacy and Safety of 0,5 mg Tizaspray® Administered Intranasally Versus Sirdalud® 2 mg Tablets, in Patients With Acute Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MDM S.p.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opera Contract Research Organization SRL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Latis Srl, Genova, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MDM S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, randomized, controlled, multicenter study with two parallel groups of patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, open label, randomized, controlled, multicenter study with two parallel
      groups of patients.

      Tizaspray® 0.5 mg (a new pharmaceutical form, liquid nasal spray solution), is proposed in
      this trial as a ready to use treatment for short term therapy of painful muscle spasms as the
      acute low back pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;hand-to-floor&quot; distance, Low Back Pain Intensity Scale (0 to 100 mm VAS), Schober test (positive/negative), Roland Disability Questionnaire (RDQ)</measure>
    <time_frame>days: 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot;hand-to-floor&quot; distance, Low Back Pain Intensity Scale (0 to 100 mm VAS), Schober test (positive/negative), Roland Disability Questionnaire (RDQ)</measure>
    <time_frame>days: 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;hand-to-floor&quot; distance, Low Back Pain Intensity Scale (0 to 100 mm VAS), Schober test (positive/negative), Roland Disability Questionnaire (RDQ)</measure>
    <time_frame>days: 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Tizaspray®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tizaspray® administered intranasally in patients with acute low back pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirdalud®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirdalud® 2 mg tablets administered in patients with acute low back pain</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tizaspray® administered intranasally</intervention_name>
    <description>0,5 mg Tizaspray® administered intranasally</description>
    <arm_group_label>Tizaspray®</arm_group_label>
    <other_name>Tizaspray®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirdalud® 2 mg tablets administered</intervention_name>
    <description>Sirdalud® 2 mg tablets administered in patients with acute low back pain</description>
    <arm_group_label>Sirdalud®</arm_group_label>
    <other_name>Sirdalud®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 65 years old

          2. Average low back pain intensity moderate to severe (≥ 60 mm in the VAS) at Visit 1

          3. Positivity to Schober test (i.e. measure &lt; 5 cm) at Visit 1

          4. Acute low back pain started at least 24 hours prior to inclusion in the trial and more
             than 6 weeks after the last episode of acute low back pain

          5. Negative pregnancy test for women of childbearing potential (to be performed at Visit
             1) and use of an acceptable mean of contraception (condom or mechanical methods) in
             the previous 2 months and for whole duration of the study

          6. Signed Informed Consent

        Exclusion Criteria:

          1. History of chronic low back pain

          2. Current treatment with drugs having significant effects at the alpha2 receptors
             whether agonist (i.e., clonidine, methyldopa) or antagonist (i.e., phenothiazines,
             imipramine)

          3. Current treatment with any other muscle relaxant or any drugs having muscle relaxant
             properties

          4. Known allergies, hypersensitivity, or intolerance to tizanidine or paracetamol or any
             excipients used in their manufacture (included patients with known rare hereditary
             problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose
             malabsorption)

          5. Signs of nasal congestion, nasal polyps, mucosal lesions of the nostrils, postnasal
             drip of any etiology or any clinically significant nasal pathology that may affect the
             absorption of study medication or the assessment of safety

          6. Evidence of clinically unstable disease, as determined by medical history, physical
             examination, that, in the Investigator's opinion, preclude entry into the study

          7. Spinal surgery within 1 year of study entry

          8. Evidence of clinical gastrointestinal malabsorption

          9. Use of steroids within 3 months of study entry or any other long-term treatment with
             steroids

         10. Use of NSAID's or other anti-inflammatory drugs 6 hours prior to study inclusion

         11. Use of fluvoxamine or ciprofloxacin, or other inhibitors of CYP1A2 such as
             antiarrhythmics (amiodarone, mexiletine, propafenone), cimetidine, fluoroquinolones
             (enoxacin, pefloxacin, norfloxacin), rofecoxib, oral contraceptives, and ticlopidine

         12. Use of hypnotics or other CNS depressants

         13. Blood pressure &lt;100/70 mmHg

         14. History of lumbar spinal stenosis, fibromyalgia, or ankylosing spondylitis

         15. Severe scoliosis

         16. More severe pain in a region other than the lower back

         17. Acute low back pain associated with chills or fever

         18. Pregnancy, breast feeding

         19. Treatment with another investigational agent within the last 30 days

         20. Known or suspected history of alcohol or drug abuse based on medical history, physical
             examination, or the Investigator's clinical judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doina Rosu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCM GADOS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Opera Contract Research Organization SRL</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300209</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Liddle SD, Baxter GD, Gracey JH. Chronic low back pain: patients' experiences, opinions and expectations for clinical management. Disabil Rehabil. 2007 Dec 30;29(24):1899-909. Epub 2007 May 4.</citation>
    <PMID>17852259</PMID>
  </reference>
  <reference>
    <citation>Frymoyer JW. Back pain and sciatica. N Engl J Med. 1988 Feb 4;318(5):291-300. Review.</citation>
    <PMID>2961994</PMID>
  </reference>
  <reference>
    <citation>van Tulder M, Becker A, Bekkering T, Breen A, del Real MT, Hutchinson A, Koes B, Laerum E, Malmivaara A; COST B13 Working Group on Guidelines for the Management of Acute Low Back Pain in Primary Care. Chapter 3. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J. 2006 Mar;15 Suppl 2:S169-91.</citation>
    <PMID>16550447</PMID>
  </reference>
  <reference>
    <citation>Cabitza P, Randelli P. Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study. Eur Rev Med Pharmacol Sci. 2008 Jul-Aug;12(4):229-35.</citation>
    <PMID>18727454</PMID>
  </reference>
  <reference>
    <citation>Górska J. [Effects of back pain treatment with tizanidine]. Ortop Traumatol Rehabil. 2005 Jun 30;7(3):306-9. Polish.</citation>
    <PMID>17611479</PMID>
  </reference>
  <reference>
    <citation>Malanga GA, Dennis RL. Use of medications in the treatment of acute low back pain. Clin Occup Environ Med. 2006;5(3):643-53, vii. Review.</citation>
    <PMID>16963380</PMID>
  </reference>
  <reference>
    <citation>Bernstein E, Carey TS, Garrett JM. The use of muscle relaxant medications in acute low back pain. Spine (Phila Pa 1976). 2004 Jun 15;29(12):1346-51.</citation>
    <PMID>15187636</PMID>
  </reference>
  <reference>
    <citation>Von Korff M, Saunders K. The course of back pain in primary care. Spine (Phila Pa 1976). 1996 Dec 15;21(24):2833-7; discussion 2838-9. Review.</citation>
    <PMID>9112707</PMID>
  </reference>
  <reference>
    <citation>Henschke N, Maher CG, Refshauge KM. A systematic review identifies five &quot;red flags&quot; to screen for vertebral fracture in patients with low back pain. J Clin Epidemiol. 2008 Feb;61(2):110-118. doi: 10.1016/j.jclinepi.2007.04.013. Epub 2007 Aug 27. Review.</citation>
    <PMID>18177783</PMID>
  </reference>
  <reference>
    <citation>Vitale DC, Piazza C, Sinagra T, Urso V, Cardì F, Drago F, Salomone S. Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. Clin Drug Investig. 2013 Dec;33(12):885-91. doi: 10.1007/s40261-013-0137-2.</citation>
    <PMID>24085590</PMID>
  </reference>
  <reference>
    <citation>Miettinen TJ, Kanto JH, Salonen MA, Scheinin M. The sedative and sympatholytic effects of oral tizanidine in healthy volunteers. Anesth Analg. 1996 Apr;82(4):817-20.</citation>
    <PMID>8615503</PMID>
  </reference>
  <reference>
    <citation>Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low-back pain: results of a double-blind multicentre study in general practice. J Int Med Res. 1988 Mar-Apr;16(2):83-91.</citation>
    <PMID>2967781</PMID>
  </reference>
  <reference>
    <citation>Fryda-Kaurimsky Z, Müller-Fassbender H. Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam. J Int Med Res. 1981;9(6):501-5.</citation>
    <PMID>6459256</PMID>
  </reference>
  <reference>
    <citation>Hennies OL. A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin. J Int Med Res. 1981;9(1):62-8.</citation>
    <PMID>6451461</PMID>
  </reference>
  <reference>
    <citation>van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003;(2):CD004252. Review.</citation>
    <PMID>12804507</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute low back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tizanidine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

